HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B

McKesson has let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of the healthcare service giant’s plan to take the unit public next year.

By FierceBiotech · Apr 27, 2026 · via FierceBiotech
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
DealsFiercePharma ↗
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big …
Apr 27, 2026
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
DealsEndpoints News ↗
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosi…
Apr 27, 2026
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
DealsFierceBiotech ↗
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking t…
Apr 25, 2026